Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis

被引:48
作者
Caviglia, Gian Paolo [1 ]
Ribaldone, Davide Giuseppe [1 ]
Abate, Maria Lorena [1 ]
Ciancio, Alessia [1 ]
Pellicano, Rinaldo [2 ]
Smedile, Antonina [1 ]
Saracco, Giorgio Maria [1 ]
机构
[1] Univ Turin, Dept Med Sci, I-10100 Turin, Italy
[2] Molinette Mauriziano Hosp, Unit Gastroenterol & Hepatol, Citta Salute & Sci, Turin, Italy
关键词
Alpha-fetoprotein; hepatocellular carcinoma; protein induced by vitamin K absence or antagonist-II; surveillance; meta-analysis; GAMMA-CARBOXY PROTHROMBIN; CLINICAL-PRACTICE GUIDELINES; PIVKA-II; DIAGNOSTIC-ACCURACY; ALPHA-FETOPROTEIN; SERUM BIOMARKERS; HEPATITIS-C; RISK; MANAGEMENT; CARBOXYPROTHROMBIN;
D O I
10.1080/00365521.2018.1459824
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objectives: In the setting of surveillance for hepatocellular carcinoma (HCC) detection, the use of serum biomarkers in addition to ultrasonography (US) is still a matter of debate. Hence, we performed a meta-analysis to evaluate the diagnostic accuracy of protein induced by vitamin K absence or antagonist-II (PIVKA-II) and alpha-fetoprotein (AFP) alone or in combination for HCC detection in patients at risk of tumor development.Materials and methods: We performed a systematic search in PubMed and Scopus database for original articles published in English from 2011 to 2017, investigating the accuracy of PIVKA-II alone or in combination with AFP (reported as area under the curve [AUC]) for HCC detection among patients at risk of tumor development. Furthermore, we focused on studies in which serum PIVKA-II was assessed by highly sensitive chemiluminescence immunoassay (CLEIA).Results: A total of 11 studies (873 patients with HCC and 1244 patients with advanced liver disease/cirrhosis) were included in the meta-analysis. The weighted summary AUC (sAUC) of PIVKA-II and AFP for the discrimination between patients with HCC and those without was 0.791 (0.746-0.837) and 0.767 (0.732-0.803), respectively. The combination of PIVKA-II+AFP results in a sAUC of 0.859 (0.837-0.882). The performance for HCC detection of PIVKA-II+AFP was significantly superior to each biomarker used alone (sAUC=0.068, p=.032 and sAUC=0.092, p<.001, respectively).Conclusion: In clinical practice, the use of PIVKA-II+AFP in addition to US examination may improve the effectiveness of surveillance among patients at risk for HCC development.
引用
收藏
页码:734 / 740
页数:7
相关论文
共 47 条
  • [1] New serum markers for detection of early hepatocellular carcinoma
    Abenavoli, Ludovico
    Boccuto, Luigi
    [J]. PANMINERVA MEDICA, 2017, 59 (04) : 281 - 282
  • [2] Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009)
    Arii, Shigeki
    Sata, Michio
    Sakamoto, Michiie
    Shimada, Mitsuo
    Kumada, Takashi
    Shiina, Shuichiro
    Yamashita, Tatsuya
    Kokudo, Norihiro
    Tanaka, Masatoshi
    Takayama, Tadatoshi
    Kudo, Masatoshi
    [J]. HEPATOLOGY RESEARCH, 2010, 40 (07) : 667 - 685
  • [3] HCC-ART score, a simple, highly sensitive and specific test for early diagnosis of hepatocellular carcinoma: a large-scale, multicentre study
    Attallah, A. M.
    Omran, M. M.
    Attallah, A. A.
    Abdallah, S. O.
    Farid, K.
    Darwish, H.
    El-Dosoky, I.
    Shaker, Y. M.
    [J]. BRITISH JOURNAL OF CANCER, 2013, 109 (06) : 1657 - 1665
  • [4] Baek YH, 2009, HEPATO-GASTROENTEROL, V56, P763
  • [5] Serial changes in serum biomarkers (GALAD model) prior to detection of HCC by ultrasound surveillance; application of statistical process control methodology
    Berhane, S.
    Johnson, P. J.
    Tada, T.
    Toyoda, H.
    Fox, R.
    Cox, T.
    Kumada, T.
    [J]. JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S628 - S628
  • [6] Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma
    Bruix, Jordi
    Reig, Maria
    Sherman, Morris
    [J]. GASTROENTEROLOGY, 2016, 150 (04) : 835 - 853
  • [7] Management of Hepatocellular Carcinoma: An Update
    Bruix, Jordi
    Sherman, Morris
    [J]. HEPATOLOGY, 2011, 53 (03) : 1020 - 1022
  • [8] Caviglia GP, 2015, MINERVA GASTROENTERO, V61, P61
  • [9] Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II
    Caviglia, Gian Paolo
    Abate, Maria L.
    Gaia, Silvia
    Petrini, Elisa
    Bosco, Caterina
    Olivero, Antonella
    Rosso, Chiara
    Ciancio, Alessia
    Pellicano, Rinaldo
    Saraco, Giorgio M.
    Rizzetto, Mario
    Smedile, Antonina
    [J]. PANMINERVA MEDICA, 2017, 59 (04) : 283 - 289
  • [10] Highly sensitive alpha-fetoprotein, Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxyprothrombin for hepatocellular carcinoma detection
    Caviglia, Gian Paolo
    Abate, Maria Lorena
    Petrini, Elisa
    Gaia, Silvia
    Rizzetto, Mario
    Smedile, Antonina
    [J]. HEPATOLOGY RESEARCH, 2016, 46 (03) : E130 - E135